His case was discussed at the North-West London, Genomic Tumour Advisor Board (GTAB) meeting (molecular tumour board [MTB]), with the aim of determining the origin of the somatic BRAF mutation detected and recommendations of further investigations. This evidence concerns the gene BRAF and neoplasm.